GtoPdb Ligand ID: 9293

Synonyms: AMG 139 | AMG-139 | MEDI2070
Compound class: Antibody
Comment: Brazikumab (AMG 139, MEDI2070) is a fully human anti-IL23A monoclonal antibody in clinical development for autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2011056600 [3].
No information available.
Summary of Clinical Use
Phase 1 clinical trials evaluating brazikumab as a monotherapy in mild to severe Crohn's disease (NCT01258205) and moderate to severe psoriasis (NCT01094093) have been completed. Phase 2 trials in subjects with active, moderate to severe Crohn's disease are ongoing (see NCT02574637 and NCT01714726).
Mechanism Of Action and Pharmacodynamic Effects
IL-23 is a potent inducer of pro-inflammatory cytokines including IL-6, IL-17, TNFα, IL-22 and GM-CSF. IL-23 is the key driver in autoimmune/inflammatory disease [1-2]. As such anti-IL-23 antibodies (targeting the p19 subunit unique to IL-23; IL23A) are being developed to ameliorate the effects of IL-23 related diseases or disorders. Such agents would be expected to inhibit IL-23 signaling, IL-23 activation of Th17 cells, IL-23 activation of NK cells, or production of proinflammatory cytokines.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01094093 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis Phase 1 Interventional Allergan
NCT01258205 Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects Phase 1 Interventional Allergan
NCT01714726 Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. Phase 2 Interventional Allergan
NCT02574637 Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease Phase 2 Interventional Allergan